59 related articles for article (PubMed ID: 27997455)
1. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the performance of algorithms for cervical cancer screening: evidence from the Ludwig-McGill cohort study.
Chevarie-Davis M; Ramanakumar AV; Ferenczy A; Villa LL; Franco EL;
Gynecol Oncol; 2013 Mar; 128(3):415-9. PubMed ID: 23234804
[TBL] [Abstract][Full Text] [Related]
3. Variation in cervical cancer screening test utilization and results in a United States-based program.
Dorismond VG; Saraiya M; Gopalani SV; Soman A; Kenney K; Miller J; Sawaya GF
Gynecol Oncol; 2024 May; 184():96-102. PubMed ID: 38301312
[TBL] [Abstract][Full Text] [Related]
4. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.
Gage JC; Ajenifuja KO; Wentzensen NA; Adepiti AC; Eklund C; Reilly M; Hutchinson M; Wacholder S; Harford J; Soliman AS; Burk RD; Schiffman M
Int J Cancer; 2012 May; 130(9):2111-7. PubMed ID: 21630264
[TBL] [Abstract][Full Text] [Related]
5. Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.
Zhang L; Xu XQ; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Feng RM; Dong L; Zhang Q; Ma JF; Sauvaget C; Zhao FH; Qiao YL; Sankaranarayanan R
Gynecol Oncol; 2018 Nov; 151(2):221-228. PubMed ID: 30269870
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus distribution and cervical cancer epidemiological characteristics in rural population of Xinjiang, China.
Wang Y; Cai YB; James W; Zhou JL; Rezhake R; Zhang Q
Chin Med J (Engl); 2021 Jul; 134(15):1838-1844. PubMed ID: 34267066
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
Fujita M; Nagashima K; Shimazu M; Suzuki M; Tauchi I; Sakuma M; Yamamoto S; Hanaoka H; Shozu M; Tsuruoka N; Kasai T; Hata A
Int J Cancer; 2024 Apr; ():. PubMed ID: 38648390
[TBL] [Abstract][Full Text] [Related]
8. Is HPV-negative cervical carcinoma a different type of cervical cancer?
Kulhan M; Bilgi A; Avci F; Ucar MG; Celik C; Kulhan NG
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9205-9212. PubMed ID: 37843334
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of age‑specific distribution of combination patterns of cytology and high‑risk HPV status on cervical intraepithelial neoplasia grade 2 or more.
Sakai M; Ohara T; Suzuki H; Kadomoto T; Inayama Y; Shitanaka S; Sumitomo M; Matsumura N; Yamanoi K
Oncol Lett; 2023 Sep; 26(3):384. PubMed ID: 37559589
[TBL] [Abstract][Full Text] [Related]
10. Genistein Inhibits Proliferation and Metastasis in Human Cervical Cancer Cells through the Focal Adhesion Kinase Signaling Pathway: A Network Pharmacology-Based In Vitro Study in HeLa Cells.
Chen T; Wang J; Li M; Wu Q; Cui S
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838908
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Human Papillomavirus Genotype Distribution in Cervical Samples.
Bakir A; Alacam S; Karabulut N; Beka H; Ozluk Y; Yilmazbayhan D; Agacfidan A
J Cytol; 2021; 38(1):44-49. PubMed ID: 33935391
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan.
Fujiwara H; Suzuki M; Morisawa H; Sayama M; Kimura K
Asian Pac J Cancer Prev; 2019 Jan; 20(1):81-85. PubMed ID: 30678384
[TBL] [Abstract][Full Text] [Related]
13. The use of conization to identify and treat severe lesions among prediagnosed CIN1 and 2 patients in Japan.
Mikami M; Ikeda M; Sato H; Iwase H; Enomoto T; Kobayashi Y; Katabuchi H
J Gynecol Oncol; 2018 Jul; 29(4):e46. PubMed ID: 29770617
[TBL] [Abstract][Full Text] [Related]
14. Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan.
Sasaki Y; Iwanari O; Arakawa I; Moriya T; Mikami Y; Iihara K; Konno R
Int J Gynecol Cancer; 2017 Mar; 27(3):523-529. PubMed ID: 27997455
[TBL] [Abstract][Full Text] [Related]
15. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
[TBL] [Abstract][Full Text] [Related]
17. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
19. Restriction of human papillomavirus DNA testing in primary cervical screening to women above age 30: systematic review.
Rebolj M; Njor SH; Lynge E
Eur J Cancer Prev; 2012 Jan; 21(1):73-81. PubMed ID: 21968690
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
